The Role of the Microbiota Gut–Liver Axis during HCV Chronic Infection: A Schematic Overview
Hepatitis C virus (HCV) still represents one of the most important worldwide health care problems. Since 2011, direct-acting antiviral (DAA) drugs have increased the number of people who have achieved a sustained virological response (SVR). Even if the program to eradicate HCV by 2030 is still ongoi...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-10-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/11/19/5936 |
| _version_ | 1797478504280883200 |
|---|---|
| author | Nadia Marascio Carmen De Caro Angela Quirino Maria Mazzitelli Emilio Russo Carlo Torti Giovanni Matera |
| author_facet | Nadia Marascio Carmen De Caro Angela Quirino Maria Mazzitelli Emilio Russo Carlo Torti Giovanni Matera |
| author_sort | Nadia Marascio |
| collection | DOAJ |
| description | Hepatitis C virus (HCV) still represents one of the most important worldwide health care problems. Since 2011, direct-acting antiviral (DAA) drugs have increased the number of people who have achieved a sustained virological response (SVR). Even if the program to eradicate HCV by 2030 is still ongoing, the SARS-CoV-2 pandemic has created a delay due to the reallocation of public health resources. HCV is characterized by high genetic variability and is responsible for hepatic and extra-hepatic diseases. Depending on the HCV genotype/subtype and comorbidities of patients, tailored treatment is necessary. Recently, it has been shown that liver damage impacts gut microbiota, altering the microbial community (dysbiosis) during persistent viral replication. An increasing number of studies are trying to clarify the role of the gut–liver axis during HCV chronic infection. DAA therapy, by restoring the gut microbiota equilibrium, seems to improve liver disease progression in both naïve and treated HCV-positive patients. In this review, we aim to discuss a snapshot of selected peer-reviewed papers concerning the interplay between HCV and the gut–liver axis. |
| first_indexed | 2024-03-09T21:33:41Z |
| format | Article |
| id | doaj.art-c7c1b59c0a1948c7a4a61b99b20c4598 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-09T21:33:41Z |
| publishDate | 2022-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-c7c1b59c0a1948c7a4a61b99b20c45982023-11-23T20:51:19ZengMDPI AGJournal of Clinical Medicine2077-03832022-10-011119593610.3390/jcm11195936The Role of the Microbiota Gut–Liver Axis during HCV Chronic Infection: A Schematic OverviewNadia Marascio0Carmen De Caro1Angela Quirino2Maria Mazzitelli3Emilio Russo4Carlo Torti5Giovanni Matera6Clinical Microbiology Unit, Department of Health Science, “Magna Graecia” University, 88100 Catanzaro, ItalySystem and Applied Pharmacology, Department of Health Science, “Magna Graecia” University, 88100 Catanzaro, ItalyClinical Microbiology Unit, Department of Health Science, “Magna Graecia” University, 88100 Catanzaro, ItalyInfectious and Tropical Diseases Unit, University Hospital of Padua, 35128 Padua, ItalySystem and Applied Pharmacology, Department of Health Science, “Magna Graecia” University, 88100 Catanzaro, ItalyInfectious and Tropical Diseases Unit, Department of Medical and Surgical Sciences, “Magna Graecia” University, 88100 Catanzaro, ItalyClinical Microbiology Unit, Department of Health Science, “Magna Graecia” University, 88100 Catanzaro, ItalyHepatitis C virus (HCV) still represents one of the most important worldwide health care problems. Since 2011, direct-acting antiviral (DAA) drugs have increased the number of people who have achieved a sustained virological response (SVR). Even if the program to eradicate HCV by 2030 is still ongoing, the SARS-CoV-2 pandemic has created a delay due to the reallocation of public health resources. HCV is characterized by high genetic variability and is responsible for hepatic and extra-hepatic diseases. Depending on the HCV genotype/subtype and comorbidities of patients, tailored treatment is necessary. Recently, it has been shown that liver damage impacts gut microbiota, altering the microbial community (dysbiosis) during persistent viral replication. An increasing number of studies are trying to clarify the role of the gut–liver axis during HCV chronic infection. DAA therapy, by restoring the gut microbiota equilibrium, seems to improve liver disease progression in both naïve and treated HCV-positive patients. In this review, we aim to discuss a snapshot of selected peer-reviewed papers concerning the interplay between HCV and the gut–liver axis.https://www.mdpi.com/2077-0383/11/19/5936HCVmicrobiotagut–liver axisdysbiosis |
| spellingShingle | Nadia Marascio Carmen De Caro Angela Quirino Maria Mazzitelli Emilio Russo Carlo Torti Giovanni Matera The Role of the Microbiota Gut–Liver Axis during HCV Chronic Infection: A Schematic Overview Journal of Clinical Medicine HCV microbiota gut–liver axis dysbiosis |
| title | The Role of the Microbiota Gut–Liver Axis during HCV Chronic Infection: A Schematic Overview |
| title_full | The Role of the Microbiota Gut–Liver Axis during HCV Chronic Infection: A Schematic Overview |
| title_fullStr | The Role of the Microbiota Gut–Liver Axis during HCV Chronic Infection: A Schematic Overview |
| title_full_unstemmed | The Role of the Microbiota Gut–Liver Axis during HCV Chronic Infection: A Schematic Overview |
| title_short | The Role of the Microbiota Gut–Liver Axis during HCV Chronic Infection: A Schematic Overview |
| title_sort | role of the microbiota gut liver axis during hcv chronic infection a schematic overview |
| topic | HCV microbiota gut–liver axis dysbiosis |
| url | https://www.mdpi.com/2077-0383/11/19/5936 |
| work_keys_str_mv | AT nadiamarascio theroleofthemicrobiotagutliveraxisduringhcvchronicinfectionaschematicoverview AT carmendecaro theroleofthemicrobiotagutliveraxisduringhcvchronicinfectionaschematicoverview AT angelaquirino theroleofthemicrobiotagutliveraxisduringhcvchronicinfectionaschematicoverview AT mariamazzitelli theroleofthemicrobiotagutliveraxisduringhcvchronicinfectionaschematicoverview AT emiliorusso theroleofthemicrobiotagutliveraxisduringhcvchronicinfectionaschematicoverview AT carlotorti theroleofthemicrobiotagutliveraxisduringhcvchronicinfectionaschematicoverview AT giovannimatera theroleofthemicrobiotagutliveraxisduringhcvchronicinfectionaschematicoverview AT nadiamarascio roleofthemicrobiotagutliveraxisduringhcvchronicinfectionaschematicoverview AT carmendecaro roleofthemicrobiotagutliveraxisduringhcvchronicinfectionaschematicoverview AT angelaquirino roleofthemicrobiotagutliveraxisduringhcvchronicinfectionaschematicoverview AT mariamazzitelli roleofthemicrobiotagutliveraxisduringhcvchronicinfectionaschematicoverview AT emiliorusso roleofthemicrobiotagutliveraxisduringhcvchronicinfectionaschematicoverview AT carlotorti roleofthemicrobiotagutliveraxisduringhcvchronicinfectionaschematicoverview AT giovannimatera roleofthemicrobiotagutliveraxisduringhcvchronicinfectionaschematicoverview |